Apellis Pharmaceuticals (NASDAQ:APLS) CFO Sells $280,300.00 in Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CFO Timothy Eugene Sullivan sold 10,000 shares of the business’s stock in a transaction on Tuesday, October 21st. The stock was sold at an average price of $28.03, for a total value of $280,300.00. Following the sale, the chief financial officer owned 110,936 shares in the company, valued at approximately $3,109,536.08. The trade was a 8.27% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Apellis Pharmaceuticals Stock Down 1.5%

Shares of NASDAQ:APLS opened at $28.17 on Friday. The company has a quick ratio of 3.16, a current ratio of 3.77 and a debt-to-equity ratio of 2.90. Apellis Pharmaceuticals, Inc. has a 52-week low of $16.10 and a 52-week high of $35.72. The stock’s fifty day simple moving average is $25.60 and its 200-day simple moving average is $21.45. The company has a market capitalization of $3.56 billion, a P/E ratio of -15.48 and a beta of 0.69.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its quarterly earnings data on Thursday, July 31st. The company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.11. Apellis Pharmaceuticals had a negative return on equity of 116.09% and a negative net margin of 30.24%.The business had revenue of $171.39 million for the quarter, compared to the consensus estimate of $187.91 million. During the same period in the prior year, the business earned ($0.30) earnings per share. The business’s revenue was down 10.6% on a year-over-year basis. As a group, equities research analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently issued reports on APLS shares. JPMorgan Chase & Co. upped their price objective on Apellis Pharmaceuticals from $35.00 to $37.00 and gave the company an “overweight” rating in a research report on Monday, August 4th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Apellis Pharmaceuticals in a research report on Friday. Morgan Stanley increased their target price on Apellis Pharmaceuticals from $25.00 to $26.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 2nd. Wells Fargo & Company began coverage on Apellis Pharmaceuticals in a research report on Wednesday, October 15th. They set an “overweight” rating and a $32.00 target price on the stock. Finally, Wall Street Zen upgraded Apellis Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, August 2nd. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, seven have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $33.47.

Hedge Funds Weigh In On Apellis Pharmaceuticals

Large investors have recently modified their holdings of the company. Assetmark Inc. raised its holdings in shares of Apellis Pharmaceuticals by 3,938.7% in the 1st quarter. Assetmark Inc. now owns 1,252 shares of the company’s stock worth $27,000 after purchasing an additional 1,221 shares during the period. Parallel Advisors LLC raised its holdings in shares of Apellis Pharmaceuticals by 80.0% in the 2nd quarter. Parallel Advisors LLC now owns 1,924 shares of the company’s stock worth $33,000 after purchasing an additional 855 shares during the period. Osaic Holdings Inc. raised its holdings in shares of Apellis Pharmaceuticals by 141.2% in the 2nd quarter. Osaic Holdings Inc. now owns 2,682 shares of the company’s stock worth $47,000 after purchasing an additional 1,570 shares during the period. GF Fund Management CO. LTD. raised its holdings in shares of Apellis Pharmaceuticals by 21.9% in the 1st quarter. GF Fund Management CO. LTD. now owns 3,185 shares of the company’s stock worth $70,000 after purchasing an additional 573 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Apellis Pharmaceuticals by 15.6% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,855 shares of the company’s stock worth $84,000 after purchasing an additional 655 shares during the period. 96.29% of the stock is currently owned by hedge funds and other institutional investors.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).